From the latest Alan Kohler interview w Eureka report, 300000 units sold in Japan represents monthly scripts for just 25000 patients.
Assuming 5% market share of 3.7 million HH sufferrers in the US is 160000 people x 12 months x $700 per script is $1.3 Billion revenue p/a. USD.
Put a P/E multiple of 15 on that and you get $20 Bil. MC USD which equates to share price north of $20 aud.
Back of the envelope but realistic inputs.
Sheesh.
From the latest Alan Kohler interview w Eureka report, 300000...
-
- There are more pages in this discussion • 6,347 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
-0.010(2.70%) |
Mkt cap ! $651.6M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 34.3¢ | $2.809M | 7.985M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 57034 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 299631 | 5 |
View Market Depth
| Last trade - 16.10pm 22/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |